AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.